{"status": "OK", "response": {"docs": [{"type_of_material": "Series", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Brett Smith, the father of two young children, was only 26 three years ago when he was found to have advanced melanoma, a deadly skin cancer. Several drugs failed to stop the cancer, while leaving him frail, depleted and ill. But two years ago, Mr. Smith began taking an experimental pill along with chemotherapy, and his tumors disappeared. He dropped the chemotherapy nearly a year ago but still takes the pill twice a day. And his disease, though it may return one day, is still at bay.", "headline": {"main": "Drugs May Turn Cancer Into Manageable Disease"}, "abstract": "Article in series Redefining Cancer examines new generation of so-called 'targeted' therapies, which could reach market in three years and transform cancer treatment by attacking underlying molecular mechanisms of disease; some experts, while warning against creating false expectations, see cancer becoming chronic disease that can be managed with medication; targeted therapy is major theme at meeting of American Society of Clinical Oncology, where there is palpable sense of excitement that progress, although limited, is being made against even stubborn cancers like those of lungs and kidney; illustrations show how drug works to attack malignant tumors by blocking chain reaction inside cancer cells that causes them to multiply and attract blood vessels for nourishment; photos (L)", "print_page": "1", "word_count": 1838, "_id": "4fd23cba8eb7c8105d7d2929", "snippet": "Brett Smith, the father of two young children, was only 26 three years ago when he was found to have advanced melanoma, a deadly skin cancer. Several drugs failed to stop the cancer, while leaving him frail, depleted and ill.     But two years ago,...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/06/06/us/drugs-may-turn-cancer-into-manageable-disease.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "AMERICAN SOCIETY OF CLINICAL ONCOLOGY"}, {"name": "subject", "value": "SURVEYS AND SERIES"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CANCER"}, {"name": "subject", "value": "CHEMOTHERAPY"}, {"name": "subject", "value": "LUNGS"}, {"name": "subject", "value": "KIDNEYS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Andrew", "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-06-06T00:00:00Z", "section_name": "Health; U.S."}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "In a novel claim testing the way that the $400 billion worldwide pharmaceutical industry is regulated, the New York State attorney general, Eliot Spitzer, sued the British-based drug giant GlaxoSmithKline yesterday, accusing the company of fraud in concealing negative information about its popular antidepressant medicine Paxil. The civil lawsuit, filed in State Supreme Court in Manhattan, contends that GlaxoSmithKline engaged in persistent fraud by failing to tell doctors that some studies of Paxil showed that the drug did not work in adolescents and might even lead to suicidal thoughts. Far from warning doctors, the suit contends, the company encouraged them to prescribe the drug for youngsters.", "headline": {"main": "Spitzer Sues a Drug Maker, Saying It Hid Negative Data"}, "abstract": "New York State Atty Gen Eliot Spitzer sues British-based GlazoSmithKline, accusing it of fraud in concealing negative information about its popular antidepressent medicine Paxil; suit claims company did not tell doctors that some studies of Paxil showed drug did not work in adolescents and might even lead to suicidal thoughts, and that company even encouraged doctors to prescribe drug for youngsters; company officials issue statement saying company 'acted responsibly' in disseminationg data from studies it conducted; although Spitzer's suit enters regulatory terrain that has been largely preserve of federal government, he does not fault Food and Drug Adm; says FDA has been hamstrung by court rulings that use free-speech arguments to limit agency's power to regulate what drug companies can say to doctors; notes that rulings do not limit his powers; FDA warned doctors last year on use of Paxil for children and adolescents; this year, it required all antidepressant makers to strengthen suicide warnings on labels; photo (M)", "print_page": "1", "word_count": 1307, "_id": "4fd2a1ed8eb7c8105d8872d3", "snippet": "In a novel claim testing the way that the $400 billion worldwide pharmaceutical industry is regulated, the New York State attorney general, Eliot Spitzer, sued the British-based drug giant GlaxoSmithKline yesterday, accusing the company of fraud in...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/06/03/business/spitzer-sues-a-drug-maker-saying-it-hid-negative-data.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "SPITZER, ELIOT L"}, {"name": "glocations", "value": "NEW YORK STATE"}, {"name": "organizations", "value": "GLAXOSMITHKLINE PLC"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "FRAUDS AND SWINDLING"}, {"name": "subject", "value": "CHILDREN AND YOUTH"}, {"name": "subject", "value": "FREEDOM OF SPEECH AND EXPRESSION"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "LABELING AND LABELS"}, {"name": "subject", "value": "MENTAL HEALTH AND DISORDERS"}, {"name": "subject", "value": "ANTIDEPRESSANTS"}, {"name": "subject", "value": "PAXIL (DRUG)"}, {"name": "subject", "value": "DEPRESSION (MENTAL)"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2004-06-03T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Science Desk", "lead_paragraph": "Arthur W. Wilson sits in his study, breathing oxygen through a nose clip and pausing frequently for the coughs that rack his body. ''I'm not suicidal,'' he said. ''I'm sane.''", "headline": {"main": "In Oregon, Choosing Death Over Suffering"}, "abstract": "Oregon's Death With Dignity law, which offers terminally ill patients opportunity to end their lives, is upheld by United States Court of Appeals for Ninth Circuit despite attempts by Attorney General John Ashcroft to punish doctors who prescribed suicide drugs under law; 171 patients with terminal illness have invoked right to take their life under Oregon law since 1997; patients hold that having control over situation, whether they use lethal drugs or not, is important and comforting; Dr Kenneth Stevens, Oregon Health and Science University department of radiation oncology chairman, opposes law; argues that assisting in suicide is contrary to doctor's role as healer; 87 percent of patients seeking assisted suicide under Oregon law cite fear of losing independence, while only 22 percent mention fear of pain; photos (L)", "print_page": "1", "word_count": 2232, "_id": "4fd256b28eb7c8105d800b39", "snippet": "Arthur W. Wilson sits in his study, breathing oxygen through a nose clip and pausing frequently for the coughs that rack his body.    ''I'm not suicidal,'' he said. ''I'm sane.''", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/06/01/science/in-oregon-choosing-death-over-suffering.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "STEVENS, KENNETH"}, {"name": "persons", "value": "ASHCROFT, JOHN"}, {"name": "glocations", "value": "OREGON"}, {"name": "organizations", "value": "OREGON HEALTH AND SCIENCE UNIVERSITY"}, {"name": "subject", "value": "DEATH AND DYING"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PAIN"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "SUICIDES AND SUICIDE ATTEMPTS"}, {"name": "subject", "value": "DECISIONS AND VERDICTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "John", "lastname": "SCHWARTZ"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "James", "lastname": "ESTRIN"}], "original": "By JOHN SCHWARTZ and JAMES ESTRIN"}, "document_type": "article", "pub_date": "2004-06-01T00:00:00Z", "section_name": "Science; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "Elderly people begin using Medicare drug discount cards on Tuesday in an experiment that has gotten off to a slow start but promises to have big implications for politics and health policy, regardless of whether it delivers big savings. The program is the first major test of the new Medicare law before the November elections. If discount cards do not deliver the promised savings, the experiment could stoke public anger over drug prices and increase political pressure for further steps to make drugs more affordable.", "headline": {"main": "DRUG DISCOUNTS BEGINNING TODAY, BUT SIGN-UPS LAG"}, "abstract": "Experiment with Medicare drug discount cards for elderly gets off to slow start but promises to have big implications for politics and health policy, as first major test of new Medicare law before Nov elections; if discount cards do not deliver promised savings, it could stoke public anger over drug prices and increase political pressure for further steps to make drugs more affordable; about 2.3 million of 4.5 million people in Medicare health maintenance organizations will receive cards automatically, without filing applications; in traditional fee-for-service Medicare program, it appears that fewer than one million people have signed up for cards; Bush administration predicts that so many Medicare beneficiaries will sign up that it will cut retail drug prices by 10 percent to 25 percent or more; Timothy F Dickman, president of Prime Therapeutics, says rise in retail drug prices over last year has wiped out savings already negotiated for members of Blue Cross plans his company helps to manage; AARP, lobby for older Americans, says value of discounts will be eroded if prices continue to rise rapidly; photo (M)", "print_page": "1", "word_count": 1543, "_id": "4fd27e868eb7c8105d847af9", "snippet": "Elderly people begin using Medicare drug discount cards on Tuesday in an experiment that has gotten off to a slow start but promises to have big implications for politics and health policy, regardless of whether it delivers big savings.    The...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/06/01/us/drug-discounts-beginning-today-but-sign-ups-lag.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "persons", "value": "DICKMAN, TIMOTHY F"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "BLUE CROSS AND BLUE SHIELD"}, {"name": "organizations", "value": "PRIME THERAPEUTICS"}, {"name": "organizations", "value": "AARP"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ELECTION ISSUES"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "AGED"}, {"name": "subject", "value": "MEDICARE"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "PRESIDENTIAL ELECTION OF 2004"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Robert", "lastname": "PEAR"}, {"organization": "", "role": "reported", "rank": 2, "firstname": "Milt", "lastname": "FREUDENHEIM"}], "original": "By ROBERT PEAR and MILT FREUDENHEIM"}, "document_type": "article", "pub_date": "2004-06-01T00:00:00Z", "section_name": "Front Page; Health; U.S."}], "meta": {"hits": 4, "offset": 0, "time": 49}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}